1 citations
,
January 2022 in “Updates in clinical dermatology” This article reviews drug-induced hair growth problems, highlighting the recognition of chemotherapy-induced alopecia as a distinct disorder, but reports no new clinical findings.
8 citations
,
January 2021 in “Fermentation” This article discusses the potential role of probiotics and synbiotics in managing hirsutism through insulin resistance but reports no new clinical results, calling for further research.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.
7 citations
,
March 2019 in “Cancer Epidemiology, Biomarkers & Prevention” This study found no evidence that finasteride use is associated with an increased risk of male breast cancer.
38 citations
,
February 2019 in “Clinical Interventions in Aging” This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.
67 citations
,
March 2018 in “The Journal of Clinical Endocrinology & Metabolism” This study reported that estrogen-progestin oral contraceptives, antiandrogens, and insulin sensitizers are more effective than placebo in treating hirsutism in women, with combination therapies generally proving superior to monotherapy.
25 citations
,
December 2017 in “The Journal of Clinical Endocrinology & Metabolism” This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
52 citations
,
March 2016 in “JAMA dermatology” This study found that hirsutism significantly negatively impacts quality of life, with self-assessed severity more strongly linked to quality-of-life impact and depressive symptoms than clinician assessments.
18 citations
,
October 2015 in “Journal of the European Academy of Dermatology and Venereology” In this study, topical eflornithine reduced hair regrowth in hirsute patients following intense pulsed light therapy, suggesting it may maintain IPL-induced hair reduction over six months.
33 citations
,
April 2015 in “Cochrane library” This review examined various treatments for hirsutism and found low to very low quality evidence suggesting that flutamide and spironolactone may help reduce hair growth, while metformin was ineffective.
17 citations
,
October 2012 in “Dermatologic clinics” This article discusses diagnostic and treatment options for excessive hair growth in women, noting a need for holistic approaches to address associated psychological issues, but it does not present new clinical findings.
22 citations
,
December 2011 in “British journal of dermatology/British journal of dermatology, Supplement” This review discusses the spectrum of unwanted facial hair in women and outlines a holistic treatment approach, emphasizing tailored regimens that address individual needs and causative factors, but provides no new clinical results.
378 citations
,
November 2011 in “Human reproduction update” This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.
22 citations
,
August 2011 in “Endocrine Practice” This review discusses the etiology, diagnosis, and management strategies for hirsutism, noting that serious underlying disorders are rare and emphasizing targeted treatment to manage testosterone's effects.
3 citations
,
July 2011 in “Expert Review of Dermatology” This article reviews the causes and treatments of hirsutism, emphasizing the importance of considering ethnic and cultural norms when interpreting grading systems, and reports no new original findings.
31 citations
,
November 2009 in “European journal of dermatology/EJD. European journal of dermatology” This paper presents a consensus-driven diagnostic evaluation form for assessing hirsutism in premenopausal women, developed by The Skin Academy for use in clinical practice.
67 citations
,
September 2008 in “Dermatologic therapy” This paper reviews causes of hirsutism in women and emphasizes the importance of identifying underlying conditions for risk assessment, though it reports no new clinical findings.
502 citations
,
February 2008 in “The Journal of Clinical Endocrinology & Metabolism” This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.
29 citations
,
April 2004 in “Annals of Pharmacotherapy” This review concluded that finasteride may reduce hirsutism scores and hair diameter in women with hyperandrogenism, but concerns about teratogenicity and long-term safety make it a secondary treatment option.
947 citations
,
February 2004 in “The Journal of Clinical Endocrinology and Metabolism” In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.
4025 citations
,
December 2003 in “Human Reproduction” This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.
78 citations
,
October 2003 in “Cochrane library” This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.
64 citations
,
May 2003 in “Journal of health psychology” This study found that women with PCOS reported higher overall psychological distress, but there was no significant link between their perceived hirsutism and this distress.
56 citations
,
April 2003 in “Fertility and Sterility” This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.
47 citations
,
August 2000 in “Endocrine Reviews” This review discusses idiopathic hirsutism, potential underlying mechanisms, and various therapeutic approaches without providing new clinical results, and emphasizes the need for further research on well-defined patient groups.
294 citations
,
August 1999 in “Journal of the American Academy of Dermatology” This study observed that the majority of side effects from laser-assisted hair removal were associated with ruby and alexandrite lasers, particularly in patients with tanned or darker skin types.
75 citations
,
March 1999 in “Fertility and sterility” This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.
15 citations
,
August 1998 in “Australasian journal of dermatology” This review discusses various treatments for hirsutism, including cosmetic techniques, anti-androgens like spironolactone, and new drugs such as finasteride and flutamide, but it reports no new clinical results.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
